Approximately 40% of the world population live in areas with the risk of malaria. Each year,
300–500 million people suffer from acute malaria, and 0.5–2.5 million die from the disease …

Malaria caused by Plasmodium falciparum is a disease that is responsible for 880,000
deaths per year worldwide. Vaccine development has proved difficult and resistance has …

The prevalence of resistance to known antimalarial drugs has resulted in the expansion of
antimalarial drug discovery efforts. Academic and nonprofit institutions are partnering with …

New drugs against malaria are greatly needed. Many approaches to antimalarial drug
discovery are available. These approaches must take into account specific concerns, in …

Despite being one of the most prevalent tropical diseases, for many years malaria was not a
commercial priority for the pharmaceutical industry. However, in response to the emergence …

This digest covers some of the most relevant progress in malaria drug discovery published
between 2010 and 2012. There is an urgent need to develop new antimalarial drugs. Such …

Malaria is one of the most prevalent and devastating infectious diseases of our time. Yet,
unfortunately, apart from artemisinin combination therapies there are relatively few effective …

The need for new antimalarials comes from the widespread resistance to those in current
use. New antimalarial targets are required to allow the discovery of chemically diverse …

The need to discover and develop new antimalarial therapeutics is overwhelming. The
annual mortality attributed to malaria, currently approximately 2.5 million, is increasing due …

Malaria is a devastating infection caused by protozoa of the genus Plasmodium. Drug
resistance is widespread, no new chemical class of antimalarials has been introduced into …